3 Reasons Why the Recent Selloff is a Buying Opportunity for XBI: A Biotech Investor’s Perspective
Biotech Sector Faces Challenges Recent Performance and Concerns Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.’s potential impact on the FDA. Concerns about Mr. Kennedy leading the HHS are likely overblown; his confirmation is uncertain, and his focus may impact the food…